BioSpace News Archive

BERG LLC today announced four abstracts showcasing the value of its Back to Biology™ approach in identifying disease signatures and mechanisms of Parkinson’s disease (PD) and other neurological disorders were presented at the annual meeting of the Society for Neuroscience (SfN) in San Diego, California, Nov. 3-7, 2018.

Quarterly Dividend Increased 40%, Driven by Strong Revenue and AFFO Growth

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be presenting at the Credit Suisse 27th Annual Healthcare Conference to be held November 12 – 15.

DexCom, Inc. today announced that it will host an Investor Day on December 4, 2018 at the Laguna Cliffs Marriott in Dana Point, California. The event will include updates on the company’s innovation pipeline, business strategy, and long-term financial outlook.

Ultivue, a life science company developing reagent-driven strategies for high-performance biological imaging in situ, today announced expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology.

Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ: NKTR) and certain of its officers.

Vita Health Products is voluntarily recalling several store-brand (Care+, Exact, Life, and Pharmasave) over-the-counter drugs used for pain or sinus relief because of a labelling issue.

Jazz Pharmaceuticals plc today announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service (NHS) in England and Wales for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)1 – two types of secondary AML.

Trovagene, Inc. today announced company highlights and financial results for the third quarter ended September 30, 2018.

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the third quarter ended September 30, 2018 and highlighted recent progress in advancing its pipeline programs, including zilucoplan for the treatment of generalized myasthenia gravis (gMG), paroxysmal nocturnal hemoglobinuria (PNH), and complement-mediated renal disorders.